Emerging HER2-targeted treatment approaches for gastroesophageal cancer in the era of chemo-immunotherapy.
New antibody drugs like trastuzumab deruxtecan improve treatment outcomes for advanced stomach cancers with HER2 mutations.
Human epidermal growth factor receptor 2 (HER2) is a key therapeutic target in gastroesophageal adenocarcinoma (GEA) and its targeting agents form the backbone of treatment for HER2-positive disease. In the second-line setting, the ADC trastuzumab deruxtecan has further improved outcomes for these patients.
What the study was
- Study design
- Observational/unspecified
- Population
- patients
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Pharmacology & therapeutics
Why it surfaced
Score 6/10 [EARLY_CANCER_DETECTION]: Observational/unspecified (Journal Article) matched 'Early cancer detection (liquid biopsy, c'. Components — novelty:1/3, relevance:3/3, design:1/2, population:1/2. Confidence: medium. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.